Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.

Genes, chromosomes & cancer - 1 Jun 2023

Wills Christopher, Watts Katie, Maughan Timothy S, Fisher David, Al-Tassan Nada A, Houlston Richard S, Escott-Price Valentina, Cheadle Jeremy P

Abstract excerpt

BACKGROUND: Therapeutic agents that specifically target patients with RAS mutant colorectal cancer (CRC) are needed. We sought potential drug targets by relating genome-wide association study and survival data in patients with advanced CRC profiled for mitogen-activated protein kinase (MAPK) pathway mutations. METHODS: In total, 694 patients from the clinical trials COIN and COIN-B had MAPK-activated CRCs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ Cells

Share to GTPase-Activating Proteins

Share to Mitogen-Activated Protein Kinases

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 36790221
DOI: 10.1002/gcc.23133
PMCID: PMC10805173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.PMID 36790221Read ↗

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in PatientsSemantic proximity Read ↗

RAS Mutations in Colorectal CancerSemantic proximity Read ↗

BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.Semantic proximity Read ↗

RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context.Semantic proximity Read ↗

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.Semantic proximity Read ↗

CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.Semantic proximity Read ↗

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors.Semantic proximity Read ↗

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.